The Influence of Age on Bispectral Index Associated With Propofol-induced Sedation
NCT ID: NCT02046720
Last Updated: 2016-03-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
70 participants
INTERVENTIONAL
2010-06-30
2013-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main objective of our study was to specifically evaluate BIS values according to age during propofol-induced sedation. LOC was measured by obtaining an OAA/S score \<2 (OAA/S2), or a deeper sedation criterion: loss of eyelash reflex (LOER). The secondary objective was to specify the influence of EMG on the displayed BIS values and its age-related modifications.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Age on Propofol-BIS Response
NCT02585284
Bispectral Index (BIS) Values Required for an Adequate Depth of Anesthesia in Elderly Patients Using Propofol
NCT03195530
Sufentanil Bispectral Index Elderly
NCT02831101
Relationship Between Bispectral Index, EEG Features, and Propofol Effect-site Concentration in Young and Elderly Patients.
NCT04774120
Determination of Propofol Target Concentration for Young and Elderly by Suppression Rate Analysis
NCT03283410
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Exclusion criteria were the presence of heart, respiratory, hepatic or renal failure; a psychiatric or neurological pathology, severe depression or dementia; gastro-oesophageal reflux, hiatal hernia; drug addiction or chronic alcoholism; obesity with a body mass index greater than 30.
The patients received no pre-medication. After insertion of a venous line, a Ringer's Lactate perfusion was initiated. Oxygen therapy at a rate of 4 litres per minute was administered in spontaneous ventilation. In case of hypoventilation (saturation (SaO2) \<95% and/or end-tidal carbon dioxide concentration (EtCO2) \>42 mmHg, manual ventilation with a mask at 10 l/min of O2 was administered.
Propofol was administered using a commercially available target-controlled infusion with an incorporated pharmacokinetic model developed by Schnider (Base Primea , Fresenius-Kabi, Brezins, FRANCE). The initial effect-site target concentration of propofol (0.5 μg/ml) was incremented by 0.5 μg/ml every 5 minutes to ensure equilibration between plasma concentration and effect site, until LOER. From the beginning of infusion until LOER patients received no other agent besides propofol for the duration of the trial.
LOC was evaluated by an independent observer using two different criteria: OAA/S score \<2 (OAA/S2) corresponding to the absence of response to moderate prodding and LOER.
To minimize interactions between verbal or tactile stimulations and BIS values, BIS values were collected before evaluation of the OAA/S score and eyelash reflex check. Time to OAA/S2 and time to LOER were measured as well as corresponding brain and plasma concentrations of propofol.
Electroencephalographic activity was monitored by BIS Quatro XP platform® electrodes and a BIS VISTA™ 1.01 monitor (Aspect medical system, MA, USA). The impedance of each electrode was kept below 5 kΩ. The sensor were reapplied if the quality of the detected signal was not suitable to provide a reliable BIS score i.e a signal quality index (SQI) better than 50%. The trace was displayed in real time and calculated data (BIS, SQI, and EMG) were recorded continuously using the archiving function integrated in the monitor. A 30 second smoothing period was set to minimize the variability and sensitivity of artifacts. BIS values were validated throughout the trial by SQI values greater than 90.
Before induction and at the end of each propofol concentration level, BIS, EMG and SQI values were recorded. As soon as the OAA/S score was less than or equal to 4, the OAA/S score and eyelash reflex were evaluated every 2 minutes independently of the increase in effect-site concentration of propofol.
Arterial pressure, heart rate, SaO2, EtCO2 were measured before induction and then every 5 minutes until the end of trial. A decrease in systolic arterial pressure ≥20 was considered as hypotension, and heart rate \<45 defined bradycardia.
Patients were included consecutively and assigned to one of the two groups according to their age: "young" 18 to 64 years (G1) and "elderly" aged 65 years and over (G2). As previously described, we considered that a difference of 15 units between the mean BIS values at LOC according to age was clinically pertinent.
Calculation of the required number of subjects was carried out to identify a difference of 15 units in the mean BIS value at LOC between both groups with a power of 90%, a 5% alpha risk, and an identical variability for these 2 groups (SD = 20). Thirty-five patients have to be included in each group.
The qualitative data were compared by a chi-squared test or when indicated by a Fisher's exact test. After verification of the normality of their distribution by a Kolmogorov Smirnov test, quantitative data were compared by a Student's t-test. A linear regression was used to measure the effect of age on BIS and EMG values at OAA/S2 and LOER. All the statistical analysis were performed using JMP 6 (SAS Institute Inc, Carry, NC, USA). Values p\< 0.05 was considered to be statistically significant.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
SCREENING
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
propofol induced sedation
Propofol was administered using a commercially available target-controlled infusion with an incorporated pharmacokinetic model developed by Schnider (Base Primea , Fresenius-Kabi, Brezins, FRANCE)12. The initial effect-site target concentration of propofol (0.5 μg/ml) was incremented by 0.5 μg/ml every 5 minutes to ensure equilibration between plasma concentration and effect site, until loss of eyelash reflex. From the beginning of infusion until LOER patients received no other agent besides propofol for the duration of the trial.
Propofol induced sedation
Propofol was administered using a commercially available target-controlled infusion with an incorporated pharmacokinetic model developed by Schnider (Base Primea , Fresenius-Kabi, Brezins, FRANCE)12. The initial effect-site target concentration of propofol (0.5 μg/ml) was incremented by 0.5 μg/ml every 5 minutes to ensure equilibration between plasma concentration and effect site, until loss of eyelash reflex. From the beginning of infusion until LOER patients received no other agent besides propofol for the duration of the trial.
The BIS index was compared between a young population (18 to 64 years old) and an elderly population (65 and more)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Propofol induced sedation
Propofol was administered using a commercially available target-controlled infusion with an incorporated pharmacokinetic model developed by Schnider (Base Primea , Fresenius-Kabi, Brezins, FRANCE)12. The initial effect-site target concentration of propofol (0.5 μg/ml) was incremented by 0.5 μg/ml every 5 minutes to ensure equilibration between plasma concentration and effect site, until loss of eyelash reflex. From the beginning of infusion until LOER patients received no other agent besides propofol for the duration of the trial.
The BIS index was compared between a young population (18 to 64 years old) and an elderly population (65 and more)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ASA I to III
* scheduled to undergo orthopaedic surgery under general anaesthesia
Exclusion Criteria
* psychiatric or neurological pathology
* severe depression or dementia
* gastro-oesophageal reflux
* hiatal hernia
* drug addiction or chronic alcoholism
* obesity with a body mass index greater than 30
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire de Saint Etienne
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sylvie PASSOT, MD
Role: PRINCIPAL_INVESTIGATOR
CHU de Saint-Etienne
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU de Saint-Etienne
Saint-Etienne, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1008181
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.